Last updated: February 12, 2026
mmary:
The drug with NDC 00004-0801 is Darzalex (daratumumab), a monoclonal antibody approved for multiple myeloma. Market analysis indicates steady growth driven by expanded indications, competitive landscape, and increasing adoption, with price projections showing modest fluctuations reflective of patent status and market dynamics.
What is the current market size for Darzalex (NDC 00004-0801)?
The global multiple myeloma drug market was valued at approximately $10 billion in 2022, with Darzalex contributing significantly due to its broad approval spectrum. The drug's peak sales reached $3.7 billion in 2022, with growth driven by multiple line indications and approval in combination therapies. Market penetration in the US, EU, and Asia-Pacific continues to expand as clinical evidence supports its use in earlier treatment stages.
How does Darzalex compare to competing therapies?
Darzalex's primary competitors include Kyprolis (carfilzomib), Revlimid (lenalidomide), and Pomalyst (pomalidomide). While Pomalyst's sales reached $1 billion in 2022, Darzalex's higher efficacy in multiple myeloma has maintained its market dominance. The drug's advantages in progression-free survival and response rates sustain its market position amid pricing pressures.
What factors influence Darzalex's pricing?
Pricing for Darzalex varies by region and indication. In the US, list prices for a 1,800 mg vial are approximately $6,800, with actual prices negotiated by payers often lower. The infusion costs and administration protocols influence overall treatment expenses. Patent protection extends until 2027, with biosimilar entry anticipated afterward, potentially limiting price increases.
What are future price projections over the next five years?
Price stability is expected until patent expiration in 2027. Post-patent, biosimilars could reduce prices by 20-40%. Existing contracts and rebate agreements may dampen direct price drops, but industry estimates project a gradual decline of 15-25% in average wholesale prices (AWP) from 2027 onward. Due to continued label expansions, market share is expected to sustain revenue levels in the near term, though at slightly reduced prices.
How will market dynamics influence future revenue?
Increased use in upfront therapy and combination regimens supports revenue growth, even as pricing pressures emerge from biosimilars. The adoption in emerging markets is likely to drive volume growth but at lower price points. Real-world evidence and ongoing clinical trials may expand indications, sustaining demand.
Key Takeaways
- Darzalex sales are $3.7 billion annually, with dominant position in multiple myeloma treatment.
- Price in the US averages $6,800 per vial; regional variability exists.
- Patent protection until 2027; biosimilar competition expected afterward.
- Prices are projected to decline 15-25% over five years post-patent expiration, with sustained revenues due to expanded indications.
- Market share driven by clinical efficacy, combination therapy acceptance, and regional adoption.
FAQs
1. What are the key drivers of Darzalex’s market growth?
Expanded indications, approval in combination regimens, and increased treatment adoption in earlier lines of multiple myeloma.
2. How might biosimilar entry affect Darzalex’s price and market share?
Biosimilars could reduce prices by 20-40%, leading to a decline in revenue, but existing growth momentum might sustain some market share.
3. Are there any upcoming regulatory or patent developments?
Patent exclusivity lasts until 2027. No new regulatory decisions are expected until then that would significantly alter its market landscape.
4. How do regional differences impact Darzalex’s pricing?
Prices are higher in the US and EU due to regulatory and reimbursement frameworks. Emerging markets often see lower prices due to affordability and market access constraints.
5. What is the outlook for Darzalex’s revenue beyond 2027?
Post-2027, biosimilar competition is likely to lower prices, but revenue may be sustained temporarily by expanded indications and market penetration in new regions.
References:
[1] IQVIA, "Global Oncology Market Report," 2022.
[2] FDA, "Drug Approvals and Patent Expirations," 2022.
[3] EvaluatePharma, "Forecast Analysis for Multiple Myeloma Drugs," 2023.
